Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:EQ NASDAQ:GALT NASDAQ:GRCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.35+22.4%$5.84$4.31▼$9.56$141.85M1.03208,659 shs763,691 shsEQEquillium$2.59+12.1%$2.05$0.27▼$2.70$146.05M1.67273,117 shs542,157 shsGALTGalectin Therapeutics$2.35+5.4%$2.59$1.21▼$7.13$146.79M0.45326,757 shs239,261 shsGRCEGrace Therapeutics$2.19-2.7%$3.71$1.79▼$5.18$34.82M0.321.09 million shs408,622 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+23.06%+27.00%+20.72%-17.85%+6.37%EQEquillium+12.12%+21.03%+34.90%+64.97%+593.81%GALTGalectin Therapeutics+5.38%+11.37%-4.86%-14.86%+80.77%GRCEGrace Therapeutics-2.67%-2.67%-48.35%-39.34%-18.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.35+22.4%$5.84$4.31▼$9.56$141.85M1.03208,659 shs763,691 shsEQEquillium$2.59+12.1%$2.05$0.27▼$2.70$146.05M1.67273,117 shs542,157 shsGALTGalectin Therapeutics$2.35+5.4%$2.59$1.21▼$7.13$146.79M0.45326,757 shs239,261 shsGRCEGrace Therapeutics$2.19-2.7%$3.71$1.79▼$5.18$34.82M0.321.09 million shs408,622 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+23.06%+27.00%+20.72%-17.85%+6.37%EQEquillium+12.12%+21.03%+34.90%+64.97%+593.81%GALTGalectin Therapeutics+5.38%+11.37%-4.86%-14.86%+80.77%GRCEGrace Therapeutics-2.67%-2.67%-48.35%-39.34%-18.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.25Hold$13.00104.72% UpsideEQEquillium 2.75Moderate Buy$7.67196.01% UpsideGALTGalectin Therapeutics 2.00Hold$11.00368.09% UpsideGRCEGrace Therapeutics 2.00Hold$6.00173.97% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, GALT, DERM, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/23/2026EQEquillium OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DERMJourney Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/16/2026EQEquillium B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.004/13/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$6.004/7/2026EQEquillium Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$10.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$61.86M2.81N/AN/A$0.96 per share6.61EQEquillium$41.10M3.98N/AN/A$0.47 per share5.51GALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$11.43M-$0.47N/A4.60N/A-14.82%-37.36%-11.02%N/AEQEquillium-$22.40M-$0.32N/AN/AN/AN/A-88.50%-72.55%N/AGALTGalectin Therapeutics-$30.84M-$0.48N/AN/AN/AN/AN/A-214.23%5/21/2026 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)Latest GRCE, GALT, DERM, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GALTGalectin Therapeutics-$0.06N/AN/AN/AN/AN/A5/13/2026Q1 2026DERMJourney Medical-$0.07-$0.08-$0.01-$0.08$15.47 million$15.96 million5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A3/30/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A3/25/2026Q4 2025DERMJourney Medical-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 million3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical0.791.791.53EQEquilliumN/A10.5810.58GALTGalectin TherapeuticsN/A2.422.42GRCEGrace TherapeuticsN/A14.9614.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%EQEquillium27.05%GALTGalectin Therapeutics11.68%GRCEGrace Therapeutics6.08%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%EQEquillium17.84%GALTGalectin Therapeutics52.60%GRCEGrace Therapeutics11.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9027.33 million23.22 millionN/AEQEquillium4063.23 million51.95 millionNot OptionableGALTGalectin Therapeutics965.83 million31.20 millionOptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/AGRCE, GALT, DERM, and EQ HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCEMay 14 at 11:01 PM | prnewswire.comGrace Therapeutics (GRCE) price target decreased by 47.83% to 6.12April 28, 2026 | msn.comGrace hit by CRL for GTx-104, shares plunge 45%April 25, 2026 | thepharmaletter.comTFDA declines Grace's stroke drug over manufacturing and packaging issues, shares slumpApril 25, 2026 | msn.comGrace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment ApplicationApril 23, 2026 | marketwatch.comFDA declines Grace's stroke drug over manufacturing and packaging issuesApril 23, 2026 | msn.comUS FDA declines to approve Grace Therapeutics' drug for a type of strokeApril 23, 2026 | reuters.comGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104April 23, 2026 | globenewswire.comGRCE stock in spotlight ahead of FDA verdict on brain bleed drug this weekApril 22, 2026 | msn.comGrace Therapeutics (NASDAQ:GRCE) Trading Up 1.9% - Should You Buy?April 16, 2026 | marketbeat.comGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026April 14, 2026 | globenewswire.comGrace Therapeutics Stock Short Interest Report | NASDAQ:GRCE | BenzingaApril 7, 2026 | benzinga.comWe're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn RateApril 4, 2026 | finance.yahoo.comGRCE Share News TodayApril 1, 2026 | uk.investing.comGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesMarch 19, 2026 | globenewswire.comGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFebruary 13, 2026 | finanznachrichten.deGrace: Fiscal Q3 Earnings SnapshotFebruary 12, 2026 | khou.comKGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFebruary 12, 2026 | globenewswire.comGrace Therapeutics Enhances Executive Severance and Change‑in‑Control TermsJanuary 14, 2026 | theglobeandmail.comGrace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferenceNovember 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 REITs to Watch as AI Data Center Spending Surpasses Office ConstructionBy Jessica Mitacek | May 7, 2026GRCE, GALT, DERM, and EQ Company DescriptionsJourney Medical NASDAQ:DERM$6.35 +1.16 (+22.35%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$6.34 -0.01 (-0.09%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Equillium NASDAQ:EQ$2.59 +0.28 (+12.12%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.50 -0.09 (-3.47%) As of 07:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Galectin Therapeutics NASDAQ:GALT$2.35 +0.12 (+5.38%) As of 05/14/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Grace Therapeutics NASDAQ:GRCE$2.19 -0.06 (-2.67%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.20 +0.02 (+0.68%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
